Abstract

Prognosis of patients with brain metastasis (BM) from renal cell carcinoma (RCC) is relevant for treatment decisions and can be estimated with the Renal Graded Prognostic Assessment (GPA). The aim of this study is to validate the updated version of this instrument in a cohort treated with Gamma Knife radiosurgery (GKRS) without prior local intracerebral therapy. Between 2007 and 2018, 106 RCC patients with BM were treated with GKRS. They were categorized according to the updated Renal GPA. Overall survival (OS), distant intracranial failure and local failure were estimated using the Kaplan-Meier method and risk factors were identified with Cox proportional hazard regressions. Median OS was 8.6months. Median OS for GPA categories 0.0-1.0 (15%), 1.5-2.0 (12%), 2.5-3.0 (35%) and 3.5-4.0 (29%) was 2.9, 5.5, 8.1 and 20.4months, respectively. Karnofsky performance status < 90, serum hemoglobin ≤ 12.5g/dL, age > 65years and time from primary diagnosis to brain metastasis < 1year were significantly related with shorter survival, while presence of extracranial disease, the volume and total number of BM had no significant impact on OS. A total count of > 4 BM was the only predictive factor for distant intracranial failure, while none of the investigated factors predicted local failure. This study confirms the updated Renal GPA in an independent cohort as a valuable instrument to estimate survival in patients with BM from RCC treated with GKRS.

Highlights

  • Prognosis of patients with brain metastasis (BM) from renal cell carcinoma (RCC) is relevant for treatment decisions and can be estimated with the Renal Graded Prognostic Assessment (GPA)

  • This study confirms the updated Renal GPA in an independent cohort as a valuable instrument to estimate survival in patients with BM from RCC treated with Gamma Knife radiosurgery (GKRS)

  • We investigate additional pre-treatment factors that may independently predict for overall survival (OS), intracranial disease progression (IDP) and intracranial local failure (ILF)

Read more

Summary

Introduction

Prognosis of patients with brain metastasis (BM) from renal cell carcinoma (RCC) is relevant for treatment decisions and can be estimated with the Renal Graded Prognostic Assessment (GPA). Metastatic renal cell carcinoma (RCC) is a relatively rare disease, with about 900 patients per year in the Netherlands [1]. 8%-28% of patients with metastatic RCC will develop brain metastases (BM) [2,3,4]. This incidence has been rising due to earlier detection with more sensitive imaging techniques combined with increased survival as a result of more effective systemic therapies. Patients with BM were excluded from the pivotal trials of the novel systemic therapies

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call